Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | 28,028 | 12,862 |
| Amortization of acquired intangible assets | 11,581 | 3,798 |
| Research and development | 100,873 | 108,973 |
| Selling, general and administrative | 86,183 | 80,961 |
| Change in the fair value of contingent consideration | — | (800) |
| Tangible asset impairment and losses on transactions, net | 927 | 77 |
| Total operating expenses | 227,592 | 205,871 |
| Income from operations | 44,959 | 970,225 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's SG&A?
- PTC Therapeutics (PTCT) reported SG&A of $86.18M in Q1 2026.
- How has PTC Therapeutics's SG&A changed year-over-year?
- PTC Therapeutics's SG&A increased by 6.5% year-over-year, from $80.96M to $86.18M.
- What is the long-term trend for PTC Therapeutics's SG&A?
- Over 4 years (2021 to 2025), PTC Therapeutics's SG&A has grown at a 5.0% compound annual growth rate (CAGR), from $285.77M to $347.14M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about PTC Therapeutics's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude